Molecular biomarkers in cervical cancer diagnosis: A critical appraisal

Expert Opinion on Medical Diagnostics

Volumn 7, Issue 4, 2013, Pages 365-377

  Litjens, Rogier J N T M ^a   Hopman, Anton H N ^a   Van De Vijver, Koen K ^a   Ramaekers, Frans C S ^a   Kruitwagen, Roy F P M ^a   Kruse, Arnold Jan ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Carcinogenesis; HPV; Integration; Methylation; P16; Screening

Indexed keywords

CELL ADHESION MOLECULE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 2A; INHIBITOR OF APOPTOSIS PROTEIN 2; MYELIN AND LYMPHOCYTE PROTEIN; PROTEIN E6; PROTEIN E7; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR MARKER;

CANCER DIAGNOSIS; CARCINOGENESIS; CELL PROLIFERATION; DIAGNOSTIC ACCURACY; GENOMIC INSTABILITY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; METHYLATION; NONHUMAN; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PROMOTER REGION; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; UTERINE CERVIX CANCER; VIRUS DNA CELL DNA INTERACTION; VIRUS ONCOGENE; WART VIRUS; CYTOCHEMISTRY; FEMALE; METABOLISM; PATHOLOGY; UTERINE CERVICAL NEOPLASMS;

FEMALE; HISTOCYTOCHEMISTRY; HUMANS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84879612071     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2013.808621     Document Type: Review

References (100)

1. Cervical cancer. NIH Consens Statement 1996;14:1-38; quiz 4p
2. Pierce Campbell CM, Menezes LJ, Paskett ED, Giuliano AR. Prevention of invasive cervical cancer in the United States: Past, present, and future. Cancer Epidemiol Biomarkers Prev 2012;21:1402-8
3. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
4. Papanicolaou GN. A new procedure for staining vaginal smears. Science 1942;95:438-9
5. De Pokomandy A, Franco E. HPV infection and cervical carcinogenesis: Epidemiology and prevention. In: Ayhan A, Reed N, Gultekin M, Dursun P, editors. Textbook of gynaecological oncology. Günes Publishing; Ankara, Turkey: 2011. p. 75
6. Siebers AG, Klinkhamer PJ, Grefte JM, et al. Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: A randomized controlled trial. JAMA 2009;302:1757-64
7. Arbyn M, Buntinx F, Van Ranst M, et al. Virologic versus cytologic triage of women with equivocal Pap smears: A meta-Analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004;96:280-93 (Pubitemid 38256273)
8. Berkhof J, de Bruijne MC, Zielinski GD, et al. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. Int J Cancer 2006;118:1759-68 (Pubitemid 43376440)
9. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-72 (Pubitemid 350137476)
10. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589-97 (Pubitemid 47598401)
11. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008;100:492-501
12. Priebe AM. 2012 cervical cancer screening guidelines and the future role of HPV testing. Clin Obstet Gynecol 2013;56:44-50
13. Berkhof J, Coupe VM, Bogaards JA, et al. The health and economic effects of HPV DNA screening in The Netherlands. Int J Cancer 2010;127:2147-58
14. Dillner J. Primary human papillomavirus testing in organized cervical screening. Curr Opin Obstet Gynecol 2013;25:11-16
15. Pepe MS, Feng Z, Janes H, et al. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: Standards for study design. J Natl Cancer Inst 2008;100:1432-8
16. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19 (Pubitemid 29406813)
17. Munoz N. Human papillomavirus and cancer: The epidemiological evidence. J Clin Virol 2000;19:1-5
18. zur Hausen H. Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer 2002;2:342-50
19. zur Hausen H. Papillomaviruses causing cancer: Evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000;92:690-8 (Pubitemid 30365529)
20. Van Muyden RC, ter Harmsel BW, Smedts FM, et al. Detection and typing of human papillomavirus in cervical carcinomas in Russian women: A prognostic study. Cancer 1999;85:2011-16 (Pubitemid 29202777)
21. Zielinski GD, Snijders PJ, Rozendaal L, et al. The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J Pathol 2003;201:535-43 (Pubitemid 38256402)
22. Bernard HU, Burk RD, Chen Z, et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010;401:70-9
23. Lungu O, Sun XW, Felix J, et al. Relationship of human papillomavirus type to grade of cervical intraepithelial neoplasia. JAMA 1992;267:2493-6
24. Baak JP, Kruse AJ, Robboy SJ, et al. Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers. J Clin Pathol 2006;59:1017-28 (Pubitemid 44570323)
25. Moody CA, Laimins LA. Human papillomavirus oncoproteins: Pathways to transformation. Nat Rev Cancer 2010;10:550-60
26. Doorbar J, Quint W, Banks L, et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012;30(Suppl 5):F55-70
27. Wentzensen N, von Knebel Doeberitz M. Biomarkers in cervical cancer screening. Dis Markers 2007;23:315-30 (Pubitemid 47015791)
28. Stanley MA. Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev 2012;25:215-22
29. Choo KB, Wang TS, Huang CJ. Analysis of relative binding affinity of E7-pRB of human papillomavirus 16 clinical variants using the yeast two-hybrid system. J Med Virol 2000;61:298-302
30. Baker CC, Phelps WC, Lindgren V, et al. Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J Virol 1987;61:962-71 (Pubitemid 17044004)
31. Schwarz E, Freese UK, Gissmann L, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 1985;314:111-14 (Pubitemid 15142033)
32. Vinokurova S, Wentzensen N, Kraus I, et al. Type-Dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res 2008;68:307-13 (Pubitemid 351380133)
33. Melsheimer P, Vinokurova S, Wentzensen N, et al. DNA aneuploidy and integration of human papillomavirus type 16 e6/e7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri. Clin Cancer Res 2004;10:3059-63 (Pubitemid 38619683)
34. Hopman AH, Smedts F, Dignef W, et al. Transition of high-grade cervical intraepithelial neoplasia to micro-invasive carcinoma is characterized by integration of HPV 16/18 and numerical chromosome abnormalities. J Pathol 2004;202:23-33 (Pubitemid 38072842)
35. Kadaja M, Isok-Paas H, Laos T, et al. Mechanism of genomic instability in cells infected with the high-risk human papillomaviruses. PLoS Pathog 2009;5:e1000397
36. Mayeaux E Jr, Thomas Cox J. Modern colposcopy textbook and atlas. Lippincott Williams & Wilkins; Philadelphia, Pennsylvania (PA), USA: 2011
37. Pett MR, Alazawi WO, Roberts I, et al. Acquisition of high-Level chromosomal instability is associated with integration of human papillomavirus type 16 in cervical keratinocytes. Cancer Res 2004;64:1359-68 (Pubitemid 38235604)
38. Schiffman M, Rodriguez AC, Chen Z, et al. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res 2010;70:3159-69
39. Ades S, Koushik A, Duarte-Franco E, et al. Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia. Int J Cancer 2008;122:2820-6 (Pubitemid 351649329)
40. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 2003(31):14-19
41. Ovestad IT, Gudlaugsson E, Skaland I, et al. Local immune response in the microenvironment of CIN2-3 with and without spontaneous regression. Mod Pathol 2010;23:1231-40
42. de Boer MA, Jordanova ES, Van Poelgeest MI, et al. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts. Int J Cancer 2007;121:2711-15 (Pubitemid 350136416)
43. Kobayashi A, Weinberg V, Darragh T, Smith-McCune K. Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol 2008;1:412-20
44. Klingelhutz AJ, Roman A. Cellular transformation by human papillomaviruses: Lessons learned by comparing high-And low-risk viruses. Virology 2012;424:77-98
45. Kruse AJ, Skaland I, Munk AC, et al. Low p53 and retinoblastoma protein expression in cervical intraepithelial neoplasia grade 3 lesions is associated with coexistent adenocarcinoma in situ. Hum Pathol 2008;39:573-8
46. Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol 2010;117:S5-10
47. Keating JT, Cviko A, Riethdorf S, et al. Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol 2001;25:884-91 (Pubitemid 32594981)
48. von Knebel Doeberitz M, Reuschenbach M, Schmidt D, Bergeron C. Biomarkers for cervical cancer screening: The role of p16(INK4a) to highlight transforming HPV infections. Expert Rev Proteomics 2012;9:149-63
49. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92:276-84 (Pubitemid 32225381)
50. Sano T, Oyama T, Kashiwabara K, et al. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998;153:1741-8 (Pubitemid 28550662)
51. Reuschenbach M, Seiz M, von Knebel Doeberitz C, et al. Evaluation of cervical cone biopsies for coexpression of p16INK4a and Ki-67 in epithelial cells. Int J Cancer 2012;130:388-94
52. Petry KU, Schmidt D, Scherbring S, et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology. Gynecol Oncol 2011;121:505-9
53. Schmidt D, Bergeron C, Denton KJ, Ridder R. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: Results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol 2011;119:158-66
54. Bergeron C, Schmidt D, Ikenberg H, Ridder R. High sensitivity and high specificity of p16/Ki-67 dual-stained cytology from screening and triage trials in over 28,000 women. Cancer Cytopathol 2010;118:305-6
55. Baak JP, Kruse AJ, Garland SM, et al. Combined p53 and retinoblastoma protein detection identifies persistent and regressive cervical high-grade squamous intraepithelial lesions. Am J Surg Pathol 2005;29:1062-6 (Pubitemid 41045551)
56. Munk AC, Gudlaugsson E, Ovestad IT, et al. Interaction of epithelial biomarkers, local immune response and condom use in cervical intraepithelial neoplasia 2-3 regression. Gynecol Oncol 2012;127:489-94
57. Demers GW, Halbert CL, Galloway DA. Elevated wild-Type p53 protein levels in human epithelial cell lines immortalized by the human papillomavirus type 16 E7 gene. Virology 1994;198:169-74
58. Huibregtse JM, Scheffner M, Howley PM. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 1991;10:4129-35 (Pubitemid 21905444)
59. Basile JR, Zacny V, Munger K. The cytokines tumor necrosis factor-Alpha (TNF-Alpha) and TNF-related apoptosisinducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the human papillomavirus-16 E7 oncoprotein. J Biol Chem 2001 ;276:22522-8
60. Filippova M, Song H, Connolly JL, et al. The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J Biol Chem 2002 ;277:21730-9 (Pubitemid 34952324)
61. Garnett TO, Duerksen-Hughes PJ. Modulation of apoptosis by human papillomavirus (HPV) oncoproteins. Arch Virol 2006 ;151:2321-35 (Pubitemid 44819331)
62. Amortegui AJ, Meyer MP, Elborne VL, Amin RM. p53, retinoblastoma gene product, and cyclin protein expression in human papillomavirus virus DNA-positive cervical intraepithelial neoplasia and invasive cancer. Mod Pathol 1995 ;8:907-12 (Pubitemid 26025967)
63. Herbsleb M, Knudsen UB, Orntoft TF, et al. Telomerase activity, MIB-1, PCNA, HPV 16 and p53 as diagnostic markers for cervical intraepithelial neoplasia. APMIS 2001 ;109:607-17 (Pubitemid 32929736)
64. Slagle BL, Kaufman RH, Reeves WC, Icenogle JP. Expression of ras, c-myc, and p53 proteins in cervical intraepithelial neoplasia. Cancer 1998 ;83:1401-8 (Pubitemid 28460092)
65. Tringler B, Gup CJ, Singh M, et al. Evaluation of p16INK4a and pRb expression in cervical squamous and glandular neoplasia. Hum Pathol 2004 ;35:689-96 (Pubitemid 38881079)
66. Howie HL, Katzenellenbogen RA, Galloway DA. Papillomavirus E6 proteins. Virology 2009 ;384:324-34
67. Klingelhutz AJ, Foster SA, McDougall JK. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature 1996 ;380:79-82 (Pubitemid 26076241)
68. Heselmeyer-Haddad K, Sommerfeld K, White NM, et al. Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer. Am J Pathol 2005 ;166:1229-38 (Pubitemid 40524445)
69. Theelen W, Reijans M, Simons G, et al. A new multiparameter assay to assess HPV 16/18, viral load and physical status together with gain of telomerase genes in HPV-related cancers. Int J Cancer 2010 ;126:959-75
70. Theelen W, Speel EJ, Herfs M, et al. Increase in viral load, viral integration, and gain of telomerase genes during uterine cervical carcinogenesis can be simultaneously assessed by the HPV 16/18 MLPA-Assay. Am J Pathol 2010 ;177:2022-33
71. Hopman AH, Theelen W, Hommelberg PP, et al. Genomic integration of oncogenic HPV and gain of the human telomerase gene TERC at 3q26 are strongly associated events in the progression of uterine cervical dysplasia to invasive cancer. J Pathol 2006 ;210:412-19 (Pubitemid 44830601)
72. McQueen F, Duvall E. Using a quality control approach to define an 'adequately cellular' liquid-based cervical cytology specimen. Cytopathology 2006 ;17:168-7
73. Burger EA, Kornor H, Klemp M, et al. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: A systematic review. Gynecol Oncol 2011 ;120:430-8
74. Bibbo M, Dytch HE, Alenghat E, et al. DNA ploidy profiles as prognostic indicators in CIN lesions. Am J Clin Pathol 1989 ;92:261-5 (Pubitemid 19228922)
75. Steinbeck RG. Proliferation and DNA aneuploidy in mild dysplasia imply early steps of cervical carcinogenesis. Acta Oncol 1997 ;36:3-12 (Pubitemid 27135153)
76. Duensing S, Duensing A, Crum CP, Munger K. Human papillomavirus type 16 E7 oncoprotein-induced abnormal centrosome synthesis is an early event in the evolving malignant phenotype. Cancer Res 2001 ;61:2356-60 (Pubitemid 32685804)
77. Duensing S, Lee LY, Duensing A, et al. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc Natl Acad Sci USA 2000 ;97:10002-7
78. Duensing S, Munger K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res 2002 ;62:7075-82 (Pubitemid 35424103)
79. Kessis TD, Connolly DC, Hedrick L, Cho KR. Expression of HPV16 E6 or E7 increases integration of foreign DNA. Oncogene 1996 ;13:427-31 (Pubitemid 26334876)
80. Boulet GA, Horvath CA, Berghmans S, Bogers J. Human papillomavirus in cervical cancer screening: Important role as biomarker. Cancer Epidemiol Biomarkers Prev 2008 ;17:810-17 (Pubitemid 351536410)
81. Park JS, Hwang ES, Park SN, et al. Physical status and expression of HPV genes in cervical cancers. Gynecol Oncol 1997 ;65:121-9 (Pubitemid 27171562)
82. Pett M, Coleman N. Integration of high-risk human papillomavirus: A key event in cervical carcinogenesis? J Pathol 2007 ;212:356-67 (Pubitemid 47099012)
83. Litjens RJ, Theelen W, Van de Pas Y, et al. Use of the HPV MLPA assay in cervical cytology for the prediction of high grade lesions. J Med Virol 2013 ; In press
84. Carcopino X, Henry M, Mancini J, et al. Significance of HPV 16 and 18 viral load quantitation in women referred for colposcopy. J Med Virol 2012 ;84:306-13
85. Dalstein V, Riethmuller D, Pretet JL, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: A longitudinal French cohort study. Int J Cancer 2003 ;106:396-403 (Pubitemid 36870403)
86. Hesselink AT, Berkhof J, Heideman DA, et al. High-risk human papillomavirus DNA load in a population-based cervical screening cohort in relation to the detection of high-grade cervical intraepithelial neoplasia and cervical cancer. Int J Cancer 2009 ;124:381-6
87. Moberg M, Gustavsson I, Gyllensten U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer 2004 ;112:854-9 (Pubitemid 39435271)
88. Cuzick J, Mayrand MH, Ronco G, et al. Chapter 10: New dimensions in cervical cancer screening. Vaccine 2006;24(Suppl 3):S3/90-7
89. Wentzensen N, Sherman ME, Schiffman M, Wang SS. Utility of methylation markers in cervical cancer early detection: Appraisal of the state-ofthe-science. Gynecol Oncol 2009 ;112:293-9
90. Spathis A, Aga E, Alepaki M, et al. Promoter methylation of p16(INK4A), hMLH1, and MGMT in liquid-based cervical cytology samples compared with clinicopathological findings and HPV presence. Infect Dis Obstet Gynecol 2011 ;2011:927861
91. Overmeer RM, Louwers JA, Meijer CJ, et al. Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women. Int J Cancer 2011 ;129:2218-25
92. Hesselink AT, Heideman DA, Steenbergen RD, et al. Combined promoter methylation analysis of CADM1 and MAL: An objective triage tool for high-risk human papillomavirus DNA-positive women. Clin Cancer Res 2011 ;17:2459-65
93. Ostor AG. Natural history of cervical intraepithelial neoplasia: A critical review. Int J Gynecol Pathol 1993 ;12:186-92 (Pubitemid 23095196)
94. Luhn P, Walker J, Schiffman M, et al. The role of co-factors in the progression from human papillomavirus infection to cervical cancer. Gynecol Oncol 2013 ;128:265-70
95. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: A retrospective cohort study. Lancet Oncol 2008 ;9:425-34
96. Munk AC, Kruse AJ, Van Diermen B, et al. Cervical intraepithelial neoplasia grade 3 lesions can regress. APMIS 2007 ;115:1409-14
97. Carreon JD, Sherman ME, Guillen D, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: Results from a histological review of population-based cervical samples. Int J Gynecol Pathol 2007 ;26:441-6 (Pubitemid 47476331)
98. Darragh TM, Colgan TJ, Cox JT, et al. The lower anogenital squamous terminology standardization project for HPV-Associated lesions: Background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis 2012 ;16:205-42
99. Trimble CL, Piantadosi S, Gravitt P, et al. Spontaneous regression of high-grade cervical dysplasia: Effects of human papillomavirus type and HLA phenotype. Clin Cancer Res 2005 ;11:4717-23 (Pubitemid 41557190)
100. Snijders PJ, Verhoef VM, Arbyn M, et al. High-risk HPV testing on self-sampled versus clinician-collected specimens: A review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int J Cancer 2013 ;132:2223-36